Biocon Ltd's Q3FY25 Quarter Results
- 31 Jan 2025
Result Summary
- Biocon Ltd reported a 6.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 14.7%.
- Its expenses for the quarter were up by 4.7% QoQ and 0.3% YoY.
- The net profit increased 199.3% QoQ and decreased 89.2% YoY.
- The earnings per share (EPS) of Biocon Ltd stood at 0.2 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 3856.20 | 3622.90 | 4519.20 | 6.4% | -14.7% |
Total Expenses | 3718.40 | 3550.50 | 3708.10 | 4.7% | 0.3% |
Profit Before Tax | 155.90 | 98.40 | 832.30 | 58.4% | -81.3% |
Tax | 74.80 | 71.30 | 54.90 | 4.9% | 36.2% |
Profit After Tax | 81.10 | 27.10 | 753.30 | 199.3% | -89.2% |
Earnings Per Share | 0.20 | -0.10 | 5.50 | -300.0% | -96.4% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Biocon Ltd is a prominent biopharmaceutical company based in India. It primarily focuses on the development and production of generic active pharmaceutical ingredients and biosimilars, serving global markets. Biocon operates in the highly competitive pharmaceutical industry, which is characterized by extensive research and development activities, regulatory approvals, and patent considerations. As of the latest known data, Biocon has been involved in significant growth initiatives, including strategic partnerships and expansions to enhance its product portfolio and market reach. Detailed and specific recent developments beyond the available data are not provided in this context.
Revenue
In the third quarter of fiscal year 2025, Biocon Ltd reported a total income of ₹3856.20 crores, which represents a 6.4% increase quarter-over-quarter from ₹3622.90 crores in Q2FY25. However, when compared year-over-year to Q3FY24, the total income reflects a decrease of 14.7% from ₹4519.20 crores. This fluctuation in revenue indicates a dynamic quarterly performance with a notable decline over the annual period. The revenue changes highlight the varying business conditions and market dynamics affecting Biocon's financial outcomes during these periods.
Profitability
The profitability metrics for Biocon Ltd in Q3FY25 show a profit before tax of ₹155.90 crores, rising significantly by 58.4% from ₹98.40 crores in the previous quarter (Q2FY25). Nonetheless, this is a substantial decrease of 81.3% from ₹832.30 crores in Q3FY24. The profit after tax for Q3FY25 stands at ₹81.10 crores, marking a remarkable increase of 199.3% from ₹27.10 crores in Q2FY25 but a sharp decline of 89.2% from ₹753.30 crores in Q3FY24. The earnings per share (EPS) for Q3FY25 is ₹0.20, which contrasts positively with the negative EPS of -₹0.10 in Q2FY25, yet it is significantly lower than the ₹5.50 reported in Q3FY24. These figures demonstrate substantial variability in Biocon's profitability over both quarterly and yearly periods.
Operating Metrics
During the third quarter of FY25, Biocon Ltd's total expenses were recorded at ₹3718.40 crores, an increase of 4.7% from ₹3550.50 crores in Q2FY25, and a slight increase of 0.3% from ₹3708.10 crores in Q3FY24. The tax expense for Q3FY25 was ₹74.80 crores, showing a marginal increase of 4.9% from ₹71.30 crores in Q2FY25, and a significant rise of 36.2% from ₹54.90 crores in Q3FY24. These operating metrics provide insight into the cost structure and tax burden Biocon faced during these periods, reflecting the company's operational adjustments and financial strategies in response to market conditions.
